Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works

The BCL-2 protein family: opposing activities that mediate cell death

Youle, R. J., & Strasser, A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,704 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works

The Bcl-2 apoptotic switch in cancer development and therapy

Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,178 · see citing works

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · see citing works

Structure of Bcl-x _L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis

Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476 · see citing works

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W. N., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 784 · see citing works

Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells

Opferman, J. T., Iwasaki, H., Ong, C. C., Suh, H., Mizuno, S.-I., Akashi, K., & Korsmeyer, S. J. (2005) · Science · doi:10.1126/science.1106114 · Cited by 573 · see citing works

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440 · see citing works

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaPreprint

Glaser, S. P., Lee, E. F., Trounson, E., Bouillet, P., Wei, A. H., Fairlie, W. D., Izon, D. J., Zuber, J. A., Rappaport, A., Herold, M. J., et al. (2012) · Genes & Development · doi:10.1101/gad.182980.111 · Cited by 427 · see citing works

Mcl-1 deficiency results in peri-implantation embryonic lethality

Rinkenberger, J. L., Horning, S., Klocke, B., Roth, K., & Korsmeyer, S. J. (2000) · Genes & Development · doi:10.1101/gad.14.1.23 · Cited by 397 · see citing works

Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity

Tao, Z., Hasvold, L. A., Wang, L., Wang, X., Petros, A. M., Park, C. H., Boghaert, E. R., Catron, N. D., Chen, J., Colman, P. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001867 · Cited by 311 · see citing works

Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737

Tahir, S. K., Yang, X., Anderson, M. G., Morgan-Lappe, S. E., Sarthy, A. V., Chen, J., Warner, R. B., Ng, S., Fesik, S. W., Elmore, S. W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2203 · Cited by 308 · see citing works

Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design

Friberg, A., Vigil, D., Zhao, B., Daniels, R. N., Burke, J. P., García-Barrantes, P. M., Camper, D. V., Chauder, B. A., Lee, T., Olejniczak, E. T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301448p · Cited by 306 · see citing works

Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins

Park, C., Bruncko, M., Adickes, J., Bauch, J. L., Ding, H., Kunzer, A. R., Marsh, K. C., Nimmer, P. M., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 301 · see citing works

Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios

Kalvass, J. C., Maurer, T. S., & Pollack, G. M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012294 · Cited by 227 · see citing works

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

Abulwerdi, F. A., Liao, C., Liu, M., Azmi, A. S., Aboukameel, A., Mady, A. S. A., Gulappa, T., Cierpicki, T., Owens, S. R., Zhang, T., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0767 · Cited by 191 · see citing works

MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes

Zhou, P., Levy, N. B., Xie, H., Qian, L., Lee, C. G., Gascoyne, R. D., & Craig, R. W. (2001) · Blood · doi:10.1182/blood.v97.12.3902 · Cited by 188 · see citing works

Small molecule Mcl-1 inhibitors for the treatment of cancer

Belmar, J., & Fesik, S. W. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.003 · Cited by 176 · see citing works

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

Zhang, H., Guttikonda, S. R., Roberts, L., Uziel, T., Semizarov, D., Elmore, S. W., Leverson, J. D., & Lam, L. T. (2010) · Oncogene · doi:10.1038/onc.2010.559 · Cited by 164 · see citing works

The Anti-Apoptotic Bcl-2 Family Member Mcl-1 Promotes T Lymphocyte Survival at Multiple Stages

Dzhagalov, I. L., Dunkle, A. D., & He, Y.-W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.521 · Cited by 160 · see citing works

Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation

Doi, K., Li, R., Sung, S., Wu, H., Liu, Y., Manieri, W., Gowda, K., Awwad, A., Dewey, A., Liu, X., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334532 · Cited by 159 · see citing works

Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell

Wei, S., Dong, K., Fang, L., Wang, X., Li, B., Shen, J., Zhang, Q., Wang, R., & Zhang, H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0697-7 · Cited by 150 · see citing works

Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo

Wendt, M. D., Wang, S., Kunzer, A. R., McClellan, W. J., Bruncko, M., Oost, T. K., Ding, H., Joseph, M. K., Zhang, H., Nimmer, P. M., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050754u · Cited by 137 · see citing works

Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function

Steimer, D. A., Boyd, K. L., Takeuchi, O., Fisher, J. K., Zambetti, G. P., & Opferman, J. T. (2008) · Blood · doi:10.1182/blood-2008-05-159145 · Cited by 123 · see citing works

Mcl-1: A Gateway to TRAIL Sensitization

Kim, S., Ricci, M., & El‐Deiry, W. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6278 · Cited by 114 · see citing works

Aberrant Reactive Oxygen and Nitrogen Species Generation in Rheumatoid Arthritis (RA): Causes and Consequences for Immune Function, Cell Survival, and Therapeutic Intervention

Phillips, D. C., Dias, I. H. K., Kitas, G. D., & Griffiths, H. R. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2607 · Cited by 113 · see citing works

Evaluation and critical assessment of putative MCL-1 inhibitors

Varadarajan, S., Vogler, M., Butterworth, M., Dinsdale, D. D., Walensky, L. D., & Cohen, G. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.79 · Cited by 101 · see citing works

Development of a high-throughput fluorescence polarization assay for Bcl-xL

Zhang, H., Nimmer, P. M., Rosenberg, S. H., Ng, S., & Joseph, M. K. (2002) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00028-3 · Cited by 95 · see citing works

3-Substituted- N -(4-Hydroxynaphthalen-1-yl)arylsulfonamides as a Novel Class of Selective Mcl-1 Inhibitors: Structure-Based Design, Synthesis, SAR, and Biological Evaluation

Abulwerdi, F. A., Liao, C., Mady, A. S. A., Gavin, J., Shen, C., Cierpicki, T., Stuckey, J. A., Showalter, H. D., & Nikolovska‐Coleska, Z. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500010b · Cited by 84 · see citing works

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein

Petros, A. M., Swann, S. L., Song, D., Swinger, K. K., Park, C., Zhang, H., Wendt, M. D., Kunzer, A. R., Souers, A. J., & Sun, C. C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.010 · Cited by 83 · see citing works

Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520

Tunquist, B. J., Woessner, R. D., & Walker, D. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0033 · Cited by 70 · see citing works

Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker

Richard, D. J., Lena, R. J., Bannister, T. D., Blake, N., Pierceall, W. E., Carlson, N. E., Keller, C. E., Koenig, M., He, Y., Minond, D., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.017 · Cited by 60 · see citing works

Ligand binding to domain-3 of human serum albumin: a chemometric analysis

Hajduk, P. J., Mendoza, R. R., Petros, A. M., Huth, J. R., Bures, M. G., Fesik, S. W., & Martin, Y. C. (2003) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1025305520585 · Cited by 50 · see citing works

3-(2-Carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex

Salituro, F. G., Harrison, B. L., Baron, B. M., Nyce, P. L., Stewart, K. T., & McDonald, I. A. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00173a003 · Cited by 50 · see citing works

Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis

Varadarajan, S., Butterworth, M., Wei, J., Pellecchia, M., Dinsdale, D. D., & Cohen, G. M. (2013) · Neoplasia · doi:10.1593/neo.13230 · Cited by 49 · see citing works

In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism.

Prueksaritanont, T., DeLuna, P., Gorham, L. M., Ma, B., Cohn, D., Pang, J., Xu, X., Leung, K., & Lin, J. H. (1998) · PubMed · Cited by 27 · see citing works

Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines

Eichhorn, J. M., Alford, S. E., Hughes, C. C., Fenical, W., & Chambers, T. C. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.411 · Cited by 25 · see citing works

Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction

Kim, Y. B., Balasis, M. E., Doi, K., Berndt, N., DuBoulay, C. J., Hu, C. A., Guida, W. C., Wang, H., Sebti, S. M., & Valle, J. R. D. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.050 · Cited by 8 · see citing works

Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies

Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D’Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,670 · see citing works

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047 · see citing works

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903 · see citing works

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619 · see citing works

Indole: A privileged scaffold for the design of anti-cancer agents

Wan, Y., Li, Y., Yan, C., Yan, M., & Tang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111691 · Cited by 521 · see citing works

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L., Chiarparin, E., Cidado, J. R., Embrey, K. J., Gangl, E. T., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 498 · see citing works

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessène, G., Strasser, A., & Kelly, G. L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 343 · see citing works

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 313 · see citing works

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance

Kapoor, I., Bodo, J., Hill, B. T., Hsi, E. D., & Almasan, A. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03144-y · Cited by 249 · see citing works

Targeting MCL-1 in hematologic malignancies: Rationale and progress

Wei, A. H., Roberts, A. W., Spencer, A. G., Rosenberg, A. S., Siegel, D. S. D., Walter, R. B., Caenepeel, S. R., Hughes, P. E., McIver, Z., Mezzi, K., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100672 · Cited by 212 · see citing works

Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain

Akçay, G., Belmonte, M. A., Aquila, B., Chuaqui, C., Hird, A. W., Lamb, M. L., Rawlins, P. B., Su, N., Tentarelli, S., Grimster, N. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2174 · Cited by 207 · see citing works

Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation

Wan, Y., Fang, G., Chen, H., Deng, X. M., & Tang, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113837 · Cited by 207 · see citing works

Potential mechanisms of resistance to venetoclax and strategies to circumvent it

Tahir, S. K., Smith, M. L., Hessler, P., Rapp, L., Idler, K. B., Park, C. H., Leverson, J. D., & Lam, L. T. (2017) · BMC Cancer · doi:10.1186/s12885-017-3383-5 · Cited by 197 · see citing works

Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer

Mérino, D., Lok, S. W., Visvader, J. E., & Lindeman, G. J. (2015) · Oncogene · doi:10.1038/onc.2015.287 · Cited by 162 · see citing works

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods

Pelz, N. F., Bian, Z., Zhao, B., Shaw, S., Tarr, J. C., Belmar, J., Gregg, C., Camper, D. V., Goodwin, C. M., Arnold, A. L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01660 · Cited by 158 · see citing works

Targeting the Bcl-2 Family in B Cell Lymphoma

Adams, C. M., Clark-Garvey, S., Porcu, P., & Eischen, C. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00636 · Cited by 158 · see citing works

Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells

Alimbetov, D. S., Askarova, S., Umbayev, B. A., Davis, T., & Kipling, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061690 · Cited by 156 · see citing works

Recent advances in the development of Mcl-1 inhibitors for cancer therapy

Hird, A. W., & Tron, A. E. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.007 · Cited by 149 · see citing works

Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells

Tong, J., Wang, P., Tan, S., Chen, D., Nikolovska‐Coleska, Z., Zou, F., Yu, J., & Zhang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3242 · Cited by 143 · see citing works

Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands

Wang, Z., He, N., Guo, Z., Niu, C., Song, T., Guo, Y., Cao, K., Wang, A., Zhu, J., Zhang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00919 · Cited by 120 · see citing works

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Xiao, Y., Nimmer, P. M., Sheppard, G. S., Bruncko, M., Hessler, P., Lu, X. L., Roberts-Rapp, L. A., Pappano, W. N., Elmore, S. W., Souers, A. J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0928 · Cited by 120 · see citing works

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Szlavik, Z., Csékei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyák, Á., Bálint, B., Murray, J. B., Davidson, J. E. P., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01234 · Cited by 117 · see citing works

Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

Phillips, D. C., Xiao, Y., Lam, L. T., Litvinovich, E., Roberts-Rapp, L. A., Souers, A. J., & Leverson, J. D. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.88 · Cited by 114 · see citing works

Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL ‐2 family members

Opferman, J. T. (2015) · FEBS Journal · doi:10.1111/febs.13472 · Cited by 113 · see citing works

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)

Papatzimas, J. W., Gorobets, E., Maity, R., Muniyat, M. I., MacCallum, J. L., Neri, P., Bahlis, N. J., & Derksen, D. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00455 · Cited by 103 · see citing works

New dimension in therapeutic targeting of BCL-2 family proteins

Besbes, S., Mirshahi, M., Pocard, M. D., & Billard, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3868 · Cited by 101 · see citing works

BH3-mimetics: recent developments in cancer therapy

Townsend, P. A., Kozhevnikova, M. V., Cexus, O., Zamyatnin, A. A., & Soond, S. M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02157-5 · Cited by 101 · see citing works

Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules

Yap, J. L., Chen, L., Lanning, M. E., & Fletcher, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01888 · Cited by 99 · see citing works

Development of Mcl-1 inhibitors for cancer therapy

Negi, A., & Murphy, P. V. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113038 · Cited by 95 · see citing works

Hot-Spots of Mcl-1 Protein

Denis, C., Santos, J. S. O., Bureau, R., & Voisin‐Chiret, A. S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00983 · Cited by 90 · see citing works

BH3-only protein BIM: An emerging target in chemotherapy

Shukla, S., Saxena, S., Singh, B. K., & Kakkar, P. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.09.002 · Cited by 87 · see citing works

Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents

Wan, Y., Dai, N., Tang, Z., & Fang, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.076 · Cited by 86 · see citing works

Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer

Guikema, J. E. J., Amiot, M., & Eldering, E. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1349754 · Cited by 80 · see citing works

Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity

Szlávik, Z., Ondi, L., Csékei, M., Paczal, A., Szabó, Z. B., Radics, G., Murray, J. B., Davidson, J. E. P., Chen, I., Davis, B. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00134 · Cited by 78 · see citing works

Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1

Murray, J. B., Davidson, J. E. P., Chen, I., Davis, B. J., Dokurno, P., Graham, C. J., Harris, R., Jordan, A. M., Matassova, N., Pedder, C., et al. (2019) · ACS Omega · doi:10.1021/acsomega.9b00611 · Cited by 76 · see citing works

BCL-2: Long and winding path from discovery to therapeutic target

Schenk, R. L., Strasser, A., & Dewson, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.100 · Cited by 72 · see citing works

Selective targeting of antiapoptotic BCL‐2 proteins in cancer

Timuçin, A. C., Başağa, H., & Kütük, Ö. (2018) · Medicinal Research Reviews · doi:10.1002/med.21516 · Cited by 71 · see citing works

Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells

Zhao, Y., He, J., Li, J., Peng, X., Wang, X., Dong, Z., Zhao, E., Liu, Y., Wu, Z., & Cui, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.529 · Cited by 71 · see citing works

Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors

Johannes, J. W., Bates, S. M., Beigie, C., Belmonte, M. A., Breen, J. N., Cao, S., Centrella, P. A., Clark, M., Cuozzo, J. W., Dumelin, C. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00464 · Cited by 67 · see citing works

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 66 · see citing works

MCL-1 inhibitors – where are we now (2019)?

Fletcher, S. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1672661 · Cited by 62 · see citing works

Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors

Lee, T., Bian, Z., Zhao, B., Hogdal, L. J., Sensintaffar, J., Goodwin, C. M., Belmar, J., Shaw, S., Tarr, J. C., Veerasamy, N., et al. (2016) · FEBS Letters · doi:10.1002/1873-3468.12497 · Cited by 62 · see citing works

Allosteric inhibition of antiapoptotic MCL-1

Lee, S., Wales, T. E., Escudero, S., Cohen, D. T., Luccarelli, J., Gallagher, C. G., Cohen, N. A., Huhn, A. J., Bird, G. H., Engen, J. R., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3223 · Cited by 59 · see citing works

Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation

Dou, Z., Zhao, D., Chen, X., Xu, C., Jin, X., Zhang, X., Wang, Y., Xie, X., Li, Q., Di, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02001-w · Cited by 53 · see citing works

Mcl-1 inhibitors: a patent review

Chen, L., & Fletcher, S. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1249848 · Cited by 51 · see citing works

Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein

Lanning, M. E., Yu, W., Yap, J. L., Chauhan, J., Chen, L., Whiting, E., Pidugu, L. S. M., Atkinson, T., Bailey, H., Li, W., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.006 · Cited by 50 · see citing works

Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent

Lü, X., Liu, Y., Orvig, C., Liang, H., & Chen, Z. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02047 · Cited by 49 · see citing works

hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents

Barile, E., Marconi, G. D., De, S. K., Baggio, C., Gambini, L., Salem, A. F., Kashyap, M. K., Castro, J. E., Kipps, T. J., & Pellecchia, M. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00962 · Cited by 47 · see citing works

Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1

Gambini, L., Udompholkul, P., Baggio, C., Muralidharan, A., Kenjić, N., Assar, Z., Perry, J. J. P., & Pellecchia, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00005 · Cited by 46 · see citing works

Allosteric sensitization of proapoptotic BAX

Pritz, J. R., Wachter, F., Lee, S., Luccarelli, J., Wales, T. E., Cohen, D. T., Coote, P. W., Heffron, G. J., Engen, J. R., Massefski, W. W., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2433 · Cited by 45 · see citing works

Overview of BCL-2 Family Proteins and Therapeutic Potentials

Huska, J. D., Lamb, H. M., & Hardwick, J. M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8861-7_1 · Cited by 43 · see citing works

Structure-based design of 3-carboxy-substituted 1,2,3,4-tetrahydroquinolines as inhibitors of myeloid cell leukemia-1 (Mcl-1)

Chen, L., Wilder, P. T., Drennen, B., Tran, J., Roth, B. M., Chesko, K. L., Shapiro, P. S., & Fletcher, S. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob02063h · Cited by 42 · see citing works

Small‐Molecule and Peptide Inhibitors of the Pro‐Survival Protein Mcl‐1

Beekman, A. M., & Howell, L. A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500497 · Cited by 42 · see citing works

Survival control of malignant lymphocytes by anti-apoptotic MCL-1

Fernández‐Marrero, Y., Spinner, S., Kaufmann, T., & Jost, P. J. (2016) · Leukemia · doi:10.1038/leu.2016.213 · Cited by 41 · see citing works

Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins

Kump, K. J., Miao, L., Mady, A. S. A., Ansari, N. H., Shrestha, U. K., Yang, Y., Pal, M., Liao, C., Perdih, A., Abulwerdi, F. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01442 · Cited by 41 · see citing works

Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA

Subramanian, A., Andronache, A., Li, Y., & Wade, M. R. (2016) · Oncotarget · doi:10.18632/oncotarget.7558 · Cited by 38 · see citing works

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines

Koss, B. S., Ryan, J. A., Budhraja, A., Szarama, K. B., Yang, X., Bathina, M., Cardone, M. H., Nikolovska‐Coleska, Z., Letai, A. G., & Opferman, J. T. (2016) · Oncotarget · doi:10.18632/oncotarget.7204 · Cited by 36 · see citing works

Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models

Lü, X., Liu, Y.-C., Orvig, C., Liang, H., & Chen, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111567 · Cited by 35 · see citing works

The chemical biology of apoptosis: Revisited after 17 years

Yang, S., Mao, Y., Zhang, H., Xu, Y., An, J., & Huang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.019 · Cited by 35 · see citing works

Progress in discovery of small-molecule modulators of protein–protein interactions via fragment screening

Magee, T. V. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.089 · Cited by 34 · see citing works

Small-molecule PROTACs: Novel Agents for Cancer Therapy

Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 32 · see citing works

Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML

Reilly, E. O., Dhami, S. P. S., Baev, D. V., Ortutay, C., McCormick, A., Morrell, R., Santocanale, C., Samali, A., Quinn, J., O'Dwyer, M. E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33982-y · Cited by 32 · see citing works

Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion

Young, A. I. J., Timpson, P., Gallego‐Ortega, D., Ormandy, C. J., & Oakes, S. R. (2017) · Cell Adhesion & Migration · doi:10.1080/19336918.2017.1393591 · Cited by 32 · see citing works

Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions

Deng, H., Han, Y., Liu, L., Zhang, H., Liu, D., Wen, J., Huang, M., & Zhao, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01998 · Cited by 31 · see citing works

Development of venetoclax for therapy of lymphoid malignancies

Zhu, H., & Almasan, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s109325 · Cited by 31 · see citing works

Structural Re‐engineering of the α‐Helix Mimetic JY‐1‐106 into Small Molecules: Disruption of the Mcl‐1–Bak‐BH3 Protein–Protein Interaction with 2,6‐Di‐Substituted Nicotinates

Drennen, B., Scheenstra, J. A., Yap, J. L., Chen, L., Lanning, M. E., Roth, B. M., Wilder, P. T., & Fletcher, S. (2016) · ChemMedChem · doi:10.1002/cmdc.201500461 · Cited by 30 · see citing works

Design, synthesis, stereochemical determination, molecular docking study, in silico pre-ADMET prediction and anti-proliferative activities of indole-pyrimidine derivatives as Mcl-1 inhibitors

Lamie, P. F., & Philoppes, J. N. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105335 · Cited by 29 · see citing works

Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid Cell Leukemia 1 Inhibitors with High Affinity, Selectivity, and Oral Bioavailability

Zhu, P., Yu, Z.-Z., Lv, Y.-F., Zhao, J., Tong, Y.-Y., You, Q., & Jiang, Z. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00682 · Cited by 28 · see citing works

The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA

Muenchow, A., Weller, S., Hinterleitner, C., Malenke, E., Bugl, S., Wirths, S., Müller, M., Schulze‐Osthoff, K., Aulitzky, W. E., Kopp, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02910-2 · Cited by 28 · see citing works

Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors

Wan, Y., Wang, J., Sun, F., Chen, M., Hou, X., & Fang, H. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.11.014 · Cited by 27 · see citing works

Mcl-1 regulates reactive oxygen species via NOX4 during chemotherapy-induced senescence

Demelash, A., Pfannenstiel, L. W., Liu, L., & Gastman, B. (2017) · Oncotarget · doi:10.18632/oncotarget.15962 · Cited by 27 · see citing works

MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma

Fu, D., Pfannenstiel, L., Demelash, A., Phoon, Y. P., Mayell, C., Cabrera, C., Liu, C., Zhao, J., Dermawan, J. K. T. K., Patil, D. T., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04334-y · Cited by 26 · see citing works

Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1

Alboreggia, G., Udompholkul, P., Baggio, C., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00277 · Cited by 22 · see citing works

DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites

Gowthaman, R., Miller, S. A., Rogers, S. A., Khowsathit, J., Lan, L., Bai, N., Johnson, D. K., Liu, C., Xu, L., Anbanandam, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00150 · Cited by 22 · see citing works

BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells

Reinhart, R., Rohner, L., Wicki, S., Fux, M., & Kaufmann, T. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.154 · Cited by 20 · see citing works

Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening

Mady, A. S. A., Liao, C., Bajwa, N., Kump, K. J., Abulwerdi, F. A., Lev, K. L., Miao, L., Grigsby, S. M., Perdih, A., Stuckey, J. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27899-9 · Cited by 19 · see citing works

Structure-Based Optimization of 3-Phenyl-N-(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide Derivatives as Selective Mcl-1 Inhibitors

Li, Y., Fan, W., Gong, Q., Tian, J., Zhou, M., Li, Q., Uwituze, L. B., Zhang, Z., Hong, R., & Wang, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00690 · Cited by 19 · see citing works

Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer

Lee, E. F., & Fairlie, W. D. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210749 · Cited by 18 · see citing works

Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology

Li, K. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127717 · Cited by 18 · see citing works

Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

Pal, P., Zhang, P., Poddar, S. K., & Zheng, G. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2116311 · Cited by 18 · see citing works

Targeting Cancer's Achilles’ Heel: Role of BCL-2 Inhibitors in Cellular Senescence and Apoptosis

Anantram, A., & Degani, M. S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0366 · Cited by 18 · see citing works

Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy

Zhu, P., Yu, Z.-Z., You, Q., & Jiang, Z. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.021 · Cited by 17 · see citing works

Identification of Small‐Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia‐1 (Mcl‐1)

Beekman, A. M., O'Connell, M. A., & Howell, L. A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500488 · Cited by 17 · see citing works

Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode

Hedir, S., Giorgi, M. D., Fogha, J., Pascale, M. D., Weiswald, L., Brotin, É., Marekha, B., Denoyelle, C., Denis, C., Suzanne, P., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.003 · Cited by 17 · see citing works

The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia

Besbes, S., Pocard, M. D., Mirshahi, M., & Billard, C. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.003 · Cited by 16 · see citing works

Proteome‐Wide Identification of On‐ and Off‐Targets of Bcl‐2 Inhibitors in Native Biological Systems by Using Affinity‐Based Probes (AfBPs)

Wang, Z., Guo, Z., Song, T., Zhang, X., He, N., Liu, P., Wang, P., & Zhang, Z. (2018) · ChemBioChem · doi:10.1002/cbic.201800380 · Cited by 16 · see citing works

Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy

Nhu, D., Lessène, G., Huang, D. C. S., & Burns, C. J. (2016) · MedChemComm · doi:10.1039/c5md00582e · Cited by 16 · see citing works

Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors

Luan, S., Ge, Q. P., Chen, Y., Dai, M., Yang, J., Li, K., Liu, D., & Zhao, L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.028 · Cited by 16 · see citing works

Macrocyclic Carbon-Linked Pyrazoles As Novel Inhibitors of MCL-1

Demin, S., Peschiulli, A., Velter, A. I., Vos, A. M., Boeck, B. D., Miller, B., Rombouts, F. J. R., Reuillon, T. D., Lento, W. E., Blanco, M. D., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00141 · Cited by 15 · see citing works

Development of a flow cytometric method for quantification of BCL‐2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL‐2 family inhibitors

Smith, M. L., Chyla, B., McKeegan, E. M., & Tahir, S. K. (2016) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21383 · Cited by 15 · see citing works

Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound

Liu, J., Tian, Z., Zhou, N., Liu, X., Liao, C., Lei, B., Li, J., Zhang, S., & Chen, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17294 · Cited by 15 · see citing works

Peptide‐Directed Binding for the Discovery of Modulators of α‐Helix‐Mediated Protein–Protein Interactions: Proof‐of‐Concept Studies with the Apoptosis Regulator Mcl‐1

Beekman, A. M., O'Connell, M. A., & Howell, L. A. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201705008 · Cited by 15 · see citing works

Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains

Wan, Y., Liu, T., Li, X., Chen, C., & Fang, H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.020 · Cited by 15 · see citing works

Understanding the Species Selectivity of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors

Zhao, B., Arnold, A. L., Coronel, M. A., Lee, J. H., Lee, T., Olejniczak, E. T., & Fesik, S. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00626 · Cited by 14 · see citing works

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer

Besbes, S., & Billard, C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.168 · Cited by 14 · see citing works

An updated patent review of Mcl-1 inhibitors (2020–2022)

Liu, J., Yin, F., Wang, Z., Song, T., & Zhang, Z. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2219394 · Cited by 13 · see citing works

Macrocyclic-based strategy in drug design: From lab to the clinic

Jin, X., Ding, N., Guo, H., & Hu, Q. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116733 · Cited by 13 · see citing works

Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1 H -indole-1-yl Moiety Binding to the P1–P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells

Deng, H., Zhang, J., Liu, L., Zhang, H., Han, Y. K., Wu, L., Jing, Y., Huang, M., & Zhao, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00643 · Cited by 13 · see citing works

Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity

Szlávik, Z., Ondi, L., Csékei, M., Paczal, A., Szabó, Z. B., Radics, G., Murray, J. B., Davidson, J. E. P., Chen, I., Davis, B. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00134 · Cited by 78 · see citing works

Abstract 3658: Structure-guided de novo design of selective Mcl-1 Inhibitors: Synthesis, structural and biochemical characterization

Mady, A. S. A., Miao, L., Perdih, A., Liao, C., Bajwa, N., Stuckey, J. A., & Nikolovska‐Coleska, Z. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-3658

3-Substituted- N -(4-Hydroxynaphthalen-1-yl)arylsulfonamides as a Novel Class of Selective Mcl-1 Inhibitors: Structure-Based Design, Synthesis, SAR, and Biological Evaluation

Abulwerdi, F. A., Liao, C., Mady, A. S. A., Gavin, J., Shen, C., Cierpicki, T., Stuckey, J. A., Showalter, H. D., & Nikolovska‐Coleska, Z. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500010b · Cited by 84 · see citing works

Abstract 2917: Design, synthesis and biological evaluation of two chemical classes as novel small molecule Mcl-1 inhibitors

Bajwa, N., Abulwerdi, F. A., Liao, C., Mady, A. S. A., Bernardo, J. D., Azmi, A. S., Cierpicki, T., Stuckey, J. A., Showalter, H. D., Mohammad, R. M., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-2917 · Cited by 8 · see citing works

Development of a series of novel Mcl-1 inhibitors bearing an indole carboxylic acid moiety

Deng, H., Huang, M., Liu, H., Zhang, H., Liu, L., Gao, B., Li, X., Li, J., Niu, Q., Zhang, Z., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106018 · Cited by 10 · see citing works